3 terminated. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 3 |
| Phase 2 | 1 | Terminated 1 |
Follow lanabecestat: new trials by email Literature Review of lanabecestat trials Research Report on lanabecestat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia Lanabecestat - Alzheimer's Disease | Phase 3 | Terminated | AstraZeneca | 421 | 2017-03-15 | 2019-12-03 |
| A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia Lanabecestat, Placebo - Alzheimer's Disease | Phase 3 | Terminated | AstraZeneca | 1722 | 2016-07-01 | 2019-12-03 |
| An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Lanabecestat, Placebo - Alzheimer´s Disease | Phase 2 / Phase 3 | Terminated | AstraZeneca | 2218 | 2014-09-30 | 2019-12-03 |
Alzheimer Disease (3) · Brain Diseases (3) · Central Nervous System Diseases (3) · Dementia (3) · Mental Disorders (3) · Nervous System Diseases (3) · Tauopathies (3) · Neurocognitive Disorders (2) · Neurodegenerative Diseases (2) · Delirium (1)
AstraZeneca (3)
Canada (3) · France (3) · Germany (3) · Japan (3) · Poland (3) · South Korea (3) · Spain (3) · United Kingdom (3) · United States (3) · Australia (2) · Belgium (2) · Hungary (2) · Italy (2) · Puerto Rico (2) · Romania (2)
PMID 27767991, PMID 31764959, PMID 33049114, PMID 40603145
2014 (1), 2015 (1), 2016 (1)